{"id":"lixisenatide-ave0010","safety":{"commonSideEffects":[{"rate":"25–40","effect":"Nausea"},{"rate":"10–15","effect":"Vomiting"},{"rate":"15–20","effect":"Diarrhea"},{"rate":"5–10","effect":"Hypoglycemia"},{"rate":"5–10","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lixisenatide binds to and activates the glucagon-like peptide-1 (GLP-1) receptor on pancreatic beta cells, enhancing glucose-dependent insulin secretion. It also suppresses glucagon secretion and slows gastric emptying, leading to reduced postprandial glucose excursions. These combined effects improve glycemic control in patients with type 2 diabetes.","oneSentence":"Lixisenatide is a GLP-1 receptor agonist that stimulates insulin secretion and reduces glucagon in response to elevated blood glucose.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:34:09.661Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT02049034","phase":"PHASE4","title":"Lixisenatide-The Effects on Glucose and Lipid Metabolism in Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Surrey","startDate":"2014-01","conditions":"Type 2 Diabetes","enrollment":8},{"nctId":"NCT05804513","phase":"PHASE4","title":"The Effect of Lixisenatide on the Effect of Pituitary Hormones","status":"UNKNOWN","sponsor":"University of Tartu","startDate":"2023-04-17","conditions":"Healthy, Type 1 Diabetes","enrollment":10},{"nctId":"NCT02244164","phase":"NA","title":"Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.","status":"TERMINATED","sponsor":"Erasme University Hospital","startDate":"2014-10","conditions":"Type 2 Diabetes, Incretinomimetics, Pancreas","enrollment":5},{"nctId":"NCT03798080","phase":"PHASE3","title":"Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-02-19","conditions":"Type 2 Diabetes Mellitus","enrollment":426},{"nctId":"NCT03798054","phase":"PHASE3","title":"Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-02-15","conditions":"Type 2 Diabetes Mellitus","enrollment":878},{"nctId":"NCT02803918","phase":"PHASE1","title":"A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2017-05-17","conditions":"Type 2 Diabetes Mellitus","enrollment":23},{"nctId":"NCT03529123","phase":"PHASE3","title":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-06-19","conditions":"Type 2 Diabetes Mellitus","enrollment":247},{"nctId":"NCT02941367","phase":"PHASE4","title":"Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan","status":"COMPLETED","sponsor":"Sanofi","startDate":"2017-02-23","conditions":"Diabetes Mellitus, Type 2","enrollment":184},{"nctId":"NCT03767543","phase":"PHASE3","title":"Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua™) in Patients With Type 2 Diabetes Mellitus (T2DM)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-03-11","conditions":"Type 2 Diabetes Mellitus","enrollment":265},{"nctId":"NCT03434119","phase":"PHASE3","title":"Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents","status":"TERMINATED","sponsor":"Sanofi","startDate":"2018-02-20","conditions":"Type 2 Diabetes Mellitus","enrollment":241},{"nctId":"NCT02787551","phase":"PHASE3","title":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-07-06","conditions":"Type 2 Diabetes Mellitus","enrollment":514},{"nctId":"NCT02752412","phase":"PHASE3","title":"Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-05-17","conditions":"Type 2 Diabetes Mellitus","enrollment":513},{"nctId":"NCT02749890","phase":"PHASE3","title":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-05-09","conditions":"Type 2 Diabetes Mellitus","enrollment":321},{"nctId":"NCT02713477","phase":"PHASE1","title":"Postprandial Glucodynamic Response to Insulin Glargine/Lixisenatide Fixed Ratio Combination in Japanese Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-04","conditions":"Type 2 Diabetes Mellitus","enrollment":20},{"nctId":"NCT02752828","phase":"PHASE3","title":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-05-23","conditions":"Type 2 Diabetes Mellitus","enrollment":521},{"nctId":"NCT02640118","phase":"NA","title":"The Impact of Lixisenatide on Postprandial Glucose Tolerance in Pancreatectomised Subjects","status":"COMPLETED","sponsor":"University Hospital, Gentofte, Copenhagen","startDate":"2015-08","conditions":"Diabetes After Total Pancreatectomy","enrollment":24},{"nctId":"NCT02231658","phase":"PHASE1","title":"Effects of Victoza® Versus Lyxumia® on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion","status":"TERMINATED","sponsor":"Profil Institut für Stoffwechselforschung GmbH","startDate":"2015-07-16","conditions":"Diabetes Mellitus","enrollment":109},{"nctId":"NCT02745470","phase":"NA","title":"Effects of a GLP-1 Receptor Agonist on Functional Activation and Connectivity of the Brain","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2016-02","conditions":"Diabetes Mellitus","enrollment":30},{"nctId":"NCT02168491","phase":"PHASE3","title":"Feasibility of Once/Daily Administered GLP/1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2014-11","conditions":"Type 2 Diabetes Mellitus","enrollment":10},{"nctId":"NCT02058147","phase":"PHASE3","title":"Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM","status":"COMPLETED","sponsor":"Sanofi","startDate":"2014-02","conditions":"Type 2 Diabetes","enrollment":1170},{"nctId":"NCT02058160","phase":"PHASE3","title":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Sanofi","startDate":"2014-01","conditions":"Type 2 Diabetes","enrollment":736},{"nctId":"NCT01798706","phase":"PHASE3","title":"Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-06","conditions":"Type 2 Diabetes","enrollment":350},{"nctId":"NCT02767596","phase":"PHASE4","title":"Evaluation of Lixisenatide Efficacy in Diabetes Mellitus Type 2 With Failure of Other GLP-1 Analog","status":"TERMINATED","sponsor":"Laniado Hospital","startDate":"2016-07-12","conditions":"Diabetes Mellitus Type 2","enrollment":2},{"nctId":"NCT01476475","phase":"PHASE2","title":"Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-11","conditions":"Type 2 Diabetes Mellitus","enrollment":323},{"nctId":"NCT02274740","phase":"PHASE2","title":"Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients","status":"TERMINATED","sponsor":"Sanofi","startDate":"2015-04","conditions":"Type II Diabetes Mellitus","enrollment":2},{"nctId":"NCT01768559","phase":"PHASE3","title":"Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-01","conditions":"Type 2 Diabetes","enrollment":894},{"nctId":"NCT00905255","phase":"PHASE3","title":"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (GETGOAL-MONO Japan LTS)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-05","conditions":"Diabetes Mellitus, Type 2","enrollment":69},{"nctId":"NCT01147250","phase":"PHASE3","title":"Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-06","conditions":"Acute Coronary Syndrome","enrollment":6068},{"nctId":"NCT00712673","phase":"PHASE3","title":"GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-06","conditions":"Diabetes Mellitus, Type 2","enrollment":680},{"nctId":"NCT00763451","phase":"PHASE3","title":"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-09","conditions":"Diabetes Mellitus, Type 2","enrollment":484},{"nctId":"NCT00713830","phase":"PHASE3","title":"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-07","conditions":"Diabetes Mellitus, Type 2","enrollment":859},{"nctId":"NCT00688701","phase":"PHASE3","title":"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-05","conditions":"Diabetes Mellitus, Type 2","enrollment":361},{"nctId":"NCT00707031","phase":"PHASE3","title":"GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-06","conditions":"Diabetes Mellitus, Type 2","enrollment":639},{"nctId":"NCT00715624","phase":"PHASE3","title":"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-07","conditions":"Diabetes Mellitus, Type 2","enrollment":496},{"nctId":"NCT00763815","phase":"PHASE3","title":"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-09","conditions":"Diabetes Mellitus Type 2","enrollment":484},{"nctId":"NCT01175473","phase":"PHASE2","title":"Effects of Lixisenatide Compared to Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-08","conditions":"Type 2 Diabetes Mellitus","enrollment":148},{"nctId":"NCT01596504","phase":"PHASE2","title":"Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-05","conditions":"Type 2 Diabetes Mellitus","enrollment":142},{"nctId":"NCT01517412","phase":"PHASE3","title":"Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-02","conditions":"Type 2 Diabetes Mellitus","enrollment":451},{"nctId":"NCT01169779","phase":"PHASE3","title":"Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-07","conditions":"Type 2 Diabetes Mellitus","enrollment":391},{"nctId":"NCT00975286","phase":"PHASE3","title":"24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-10","conditions":"Type 2 Diabetes Mellitus","enrollment":446},{"nctId":"NCT00866658","phase":"PHASE3","title":"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-03","conditions":"Diabetes Mellitus, Type 2","enrollment":311},{"nctId":"NCT00976937","phase":"PHASE3","title":"24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-08","conditions":"Type 2 Diabetes Mellitus","enrollment":319},{"nctId":"NCT02200991","phase":"PHASE4","title":"Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin Glargine","status":"COMPLETED","sponsor":"Sanofi","startDate":"2014-08","conditions":"Type 2 Diabetes Mellitus","enrollment":136},{"nctId":"NCT02276196","phase":"PHASE4","title":"Effect of LIXIsenatide on the Renal System","status":"COMPLETED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2014-09","conditions":"Diabetic Kidney Disease, Diabetic Nephropathy, Diabetes Mellitus","enrollment":40},{"nctId":"NCT02020629","phase":"PHASE4","title":"Study on Lixisenatide and Counterregulation to Hypoglycemia","status":"COMPLETED","sponsor":"Lund University","startDate":"2013-12","conditions":"Type 2 Diabetes","enrollment":18},{"nctId":"NCT02308254","phase":"PHASE1, PHASE2","title":"Drug Trial of Lixisenatide on Gastric Emptying and Blood Pressure Drops in Type 2 Diabetics and Healthy People","status":"UNKNOWN","sponsor":"Royal Adelaide Hospital","startDate":"2013-11","conditions":"Diabetes Mellitus, Gastroparesis","enrollment":30},{"nctId":"NCT01940965","phase":"PHASE3","title":"Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-09","conditions":"Type 2 Diabetes Mellitus","enrollment":294},{"nctId":"NCT01632163","phase":"PHASE3","title":"Assessment of the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin +/- Metformin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-10","conditions":"Type 2 Diabetes Mellitus","enrollment":447},{"nctId":"NCT01960179","phase":"PHASE3","title":"Safety And Tolerability Of Lixisenatide In Monotherapy In Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-11","conditions":"Type 2 Diabetes Mellitus","enrollment":361},{"nctId":"NCT01910194","phase":"PHASE2","title":"Impact of Combined of Lantus(Insulin Glargine) and Lyxumia (Lixisenatide) on Insulin Secretion and Gastric Emptying","status":"COMPLETED","sponsor":"Profil Institut für Stoffwechselforschung GmbH","startDate":"2013-12","conditions":"Diabetes Mellitus","enrollment":39},{"nctId":"NCT01572649","phase":"PHASE1","title":"Evaluation of the Blood Levels of the Drug (Lixisenatide), the Plasma Glucose Levels and Safety in Paediatric and Adult Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-05","conditions":"Type 2 Diabetes Mellitus","enrollment":24},{"nctId":"NCT00299871","phase":"PHASE2","title":"Dose Ranging Study of the GLP-1 Agonist AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-02","conditions":"Type 2 Diabetes","enrollment":542},{"nctId":"NCT00931372","phase":"PHASE1","title":"Lixisenatide for Restoration of Insulin Release in Subjects With Diabetes Mellitus Type 2","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-06","conditions":"Diabetes Mellitus, Type 2","enrollment":22},{"nctId":"NCT01146678","phase":"PHASE1","title":"Relative Bioavailability and Activity of Different Formulations of Insulin Glargine and Lixisenatide in Patients With Diabetes Mellitus Type 1","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-06","conditions":"Type 1 Diabetes Mellitus","enrollment":22}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lyxumia","Lyxumia®","Device: Disposable self-injector prefilled pen (Delta 14®)"],"phase":"marketed","status":"active","brandName":"Lixisenatide (AVE0010)","genericName":"Lixisenatide (AVE0010)","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lixisenatide is a GLP-1 receptor agonist that stimulates insulin secretion and reduces glucagon in response to elevated blood glucose. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}